Back to Search
Start Over
Efficacy of mycophenolate mofetil in the treatment of chronic graft-versus-host disease
- Source :
-
Biology of Blood & Marrow Transplantation . Apr2005, Vol. 11 Issue 4, p307-313. 7p. - Publication Year :
- 2005
-
Abstract
- Abstract: Current treatment of chronic graft-versus-host disease (cGVHD) with prednisone (PSE) alone or with added cyclosporine or tacrolimus still has a very high failure and complication rate, and new treatment approaches are needed for both primary and salvage therapy. Mycophenolate mofetil (MMF) is an immunosuppressive agent currently in use for acute graft-versus-host disease prophylaxis. To determine whether MMF had activity in the treatment of cGVHD, we added MMF to standard cyclosporine, tacrolimus, and/or PSE as salvage/second-line (n = 24) or first-line (n = 10) therapy in 34 patients. Nine (90%) of 10 patients receiving first-line and 18 (75%) of 24 receiving second-line MMF therapy responded. Twelve (35%) patients had a complete remission, 15 (44%) had a partial remission, 5 (15%) had stable disease, and only 2 (6%) had progressive disease. Out of 30 patients receiving PSE, 22 (73%) were able to decrease PSE doses (median decrease of 50%; range, 25%–100%). With a median follow-up of 24 months (range, 6–28 months), 29 (85%) patients are alive. Three patients had to discontinue MMF because of abdominal cramps within 3 months of starting treatment. These data suggest that MMF is an active, well-tolerated agent in the treatment of cGVHD and may have a beneficial effect on the survival of patients with this complication. [Copyright &y& Elsevier]
- Subjects :
- *IMMUNOSUPPRESSIVE agents
*PLANT propagation
*CYCLOSPORINE
*STANDARD deviations
Subjects
Details
- Language :
- English
- ISSN :
- 10838791
- Volume :
- 11
- Issue :
- 4
- Database :
- Academic Search Index
- Journal :
- Biology of Blood & Marrow Transplantation
- Publication Type :
- Academic Journal
- Accession number :
- 16873080
- Full Text :
- https://doi.org/10.1016/j.bbmt.2005.01.011